<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01840228</url>
  </required_header>
  <id_info>
    <org_study_id>201301148</org_study_id>
    <nct_id>NCT01840228</nct_id>
  </id_info>
  <brief_title>Vaginal Progesterone for the Prevention of Preterm Birth in Women With Arrested Preterm Labor</brief_title>
  <acronym>PAL</acronym>
  <official_title>Vaginal Progesterone for the Prevention of Preterm Birth in Women With Arrested Preterm Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm birth, defined as birth before 37 weeks' gestation, is a leading cause of infant
      death and disease. Progesterone is the single most effective intervention in the prevention
      of preterm birth. However, current use of this therapy is limited to certain high-risk groups
      including women with a history of preterm birth and women with a short cervix. This study
      seeks to evaluate the efficacy of this preventive therapy in another high-risk group: women
      with arrested preterm labor. The investigators hypothesize that administration of vaginal
      progesterone in women who present with preterm labor but remain undelivered 12 hours after
      cessation of short-term therapy to inhibit contractions will result in lower rates of preterm
      birth before 37 weeks' than will administration of placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RESEARCH DESIGN AND METHODS

      The investigators will perform a randomized, blinded, placebo-controlled trial to evaluate
      the use of vaginal progesterone in women with arrested preterm labor after 24 weeks'
      gestation to reduce the risk of preterm birth before 37 weeks' gestation. Women enrolled in
      the study will be randomized to daily vaginal administration of progesterone (200 mg) or
      placebo from time of enrollment until 36 6/7 weeks' gestation. Women will be eligible if they
      have a singleton or twin gestation between 24 0/7 and 33 6/7 weeks' gestation and initially
      present with regular uterine contractions and a clinical diagnosis of preterm labor but
      remain undelivered without further cervical change 12 hours after discontinuation of acute
      tocolytic therapy. Women may also participate if it has been less than if they are considered
      eligible for discharge based on attending physician judgement prior to the 12 hour period of
      time.

      Randomization and Blinding- Participants in the study will be randomized using a
      computer-generated randomization scheme with 1:1 allocation to receive progesterone or
      placebo. Investigators and research team members, participants, and the obstetric providers
      will be blinded to the allocated intervention.

      Procedures-

        -  Data collection- Information will be recorded from the participant's medical record.
           Additional study information not included in the medical record will be obtained
           directly from the participant in an interview with the research team member.

        -  Follow-up- Regardless of whether the participant remains hospitalized or is discharged
           prior to delivery, she will meet with a study coordinator every 2 weeks. During the
           follow-up visit, a study team member will discuss compliance with the study drug and
           possible side effects. The participant will fill out a 1-page questionnaire that asks
           questions about compliance and side effects. This information will be recorded and
           provided to the Data Safety and Monitoring Board at the midpoint review.

      SAMPLE SIZE ESTIMATION

      The investigators plan to enroll 120 patients, with a 1:1 allocation to treatment and
      placebo. This sample size is adequate to detect a one-half reduction in the primary outcome,
      delivery before 37 weeks.

      STATISTICAL ANALYSIS

      Baseline characteristics of women randomized to progesterone will be compared with women
      randomized to placebo. Rates of delivery before 37 weeks' gestation will be compared among
      the groups using the Chi-square test. Secondary outcomes will be evaluated using the
      Chi-square test for binary outcomes and the Student t-test for continuous outcomes. Length of
      time from enrollment to delivery will be analyzed using Kaplan-Meier curves and the Cox
      proportional hazards model. All analyses will be performed using the intention-to-treat
      principle.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment rate
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">May 7, 2018</completion_date>
  <primary_completion_date type="Actual">May 7, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Delivered Before 37 Weeks'</measure>
    <time_frame>Duration of current pregnancy, anticipated maximum 18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Delivered Before 34 Weeks'</measure>
    <time_frame>Duration of current pregnancy, anticipated maximum 18 weeks</time_frame>
    <description>Evaluated in women enrolled prior to 32 weeks gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delivery Within 2 Weeks of Randomization</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Weeks Pregnancy Prolongation</measure>
    <time_frame>Duration of current pregnancy, anticipated maximum 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant Birth Weight</measure>
    <time_frame>Day of delivery in current pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Intensive Care Unit Admission</measure>
    <time_frame>Followed for duration of neonatal hospital stay, estimated maximum 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chorioamnionitis</measure>
    <time_frame>Duration of current pregnancy, anticipated maximum 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Neonatal Outcome</measure>
    <time_frame>Followed for duration of neonatal hospital stay, estimated maximum 16 weeks</time_frame>
    <description>A composite neonatal outcome comprising neonatal death, respiratory distress syndrome, bronchopulmonary dysplasia, severe (grade III/IV) interventricular hemorrhage, necrotizing enterocolitis, and sepsis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Premature Birth</condition>
  <condition>Obstetric Labor, Premature</condition>
  <arm_group>
    <arm_group_label>Micronized progesterone suppository</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo suppository</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One placebo suppository vaginally daily until 36 6/7 weeks' gestation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micronized progesterone suppository</intervention_name>
    <arm_group_label>Micronized progesterone suppository</arm_group_label>
    <arm_group_label>Placebo suppository</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton or twin gestation

          -  Estimated gestational age between 24 0/7 and 33 6/7 weeks' gestation

          -  Initially present with regular contractions and clinical diagnosis of preterm labor
             but remain undelivered with 1) no further cervical change 12 hours after
             discontinuation of acute tocolytic therapy; or 2) be considered eligible for discharge
             based on attending physician judgment prior to the 12 hour period of time

          -  The participant's cervix must be at least 1 cm at the time of enrollment

        Exclusion Criteria:

          -  Non-English speaking

          -  Rupture of membranes

          -  Chorioamnionitis

          -  Non-reassuring fetal status

          -  Maternal indication for delivery

          -  Placental abruption

          -  Intrauterine fetal demise

          -  Prenatally diagnosed major fetal anomaly

          -  Cervical cerclage in place

          -  Previous administration of progesterone during the current pregnancy for a history of
             preterm birth or short cervix

          -  Participant is either unwilling or unable to attend follow-up study visits following
             hospital discharge
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George A Macones, MD, MSCE</last_name>
    <role>Study Chair</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heather A Frey, MD, MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine/ Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lyell DJ, Pullen KM, Mannan J, Chitkara U, Druzin ML, Caughey AB, El-Sayed YY. Maintenance nifedipine tocolysis compared with placebo: a randomized controlled trial. Obstet Gynecol. 2008 Dec;112(6):1221-6. doi: 10.1097/AOG.0b013e31818d8386.</citation>
    <PMID>19037029</PMID>
  </reference>
  <reference>
    <citation>Likis FE, Edwards DR, Andrews JC, Woodworth AL, Jerome RN, Fonnesbeck CJ, McKoy JN, Hartmann KE. Progestogens for preterm birth prevention: a systematic review and meta-analysis. Obstet Gynecol. 2012 Oct;120(4):897-907. Review.</citation>
    <PMID>22955308</PMID>
  </reference>
  <reference>
    <citation>Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, Vijayaraghavan J, Trivedi Y, Soma-Pillay P, Sambarey P, Dayal A, Potapov V, O'Brien J, Astakhov V, Yuzko O, Kinzler W, Dattel B, Sehdev H, Mazheika L, Manchulenko D, Gervasi MT, Sullivan L, Conde-Agudelo A, Phillips JA, Creasy GW; PREGNANT Trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011 Jul;38(1):18-31. doi: 10.1002/uog.9017. Epub 2011 Jun 15.</citation>
    <PMID>21472815</PMID>
  </reference>
  <reference>
    <citation>Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007 Aug 2;357(5):462-9.</citation>
    <PMID>17671254</PMID>
  </reference>
  <reference>
    <citation>Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2008 Feb;48(1):58-63. doi: 10.1111/j.1479-828X.2007.00803.x.</citation>
    <PMID>18275573</PMID>
  </reference>
  <reference>
    <citation>Arikan I, Barut A, Harma M, Harma IM. Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor. Gynecol Obstet Invest. 2011;72(4):269-73. doi: 10.1159/000328719. Epub 2011 Nov 12.</citation>
    <PMID>22086108</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2013</study_first_posted>
  <results_first_submitted>May 7, 2019</results_first_submitted>
  <results_first_submitted_qc>May 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2019</results_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preterm</keyword>
  <keyword>Progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 11, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01840228/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Micronized Progesterone Suppository</title>
          <description>Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
        </group>
        <group group_id="P2">
          <title>Placebo Suppository</title>
          <description>One placebo suppository vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Micronized Progesterone Suppository</title>
          <description>Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
        </group>
        <group group_id="B2">
          <title>Placebo Suppository</title>
          <description>One placebo suppository vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.8" spread="5.5"/>
                    <measurement group_id="B2" value="26.3" spread="4.6"/>
                    <measurement group_id="B3" value="26.0" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parity</title>
          <units>births</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="B2" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="B3" value="1" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" spread="7.9"/>
                    <measurement group_id="B2" value="25.4" spread="8.3"/>
                    <measurement group_id="B3" value="25.3" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior preterm birth</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Twin gestation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Single</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Married</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Divorced</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insurance use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Public insurance</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Private insurance</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age at enrollment</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.6" lower_limit="29.9" upper_limit="32.9"/>
                    <measurement group_id="B2" value="30.4" lower_limit="28.1" upper_limit="32.6"/>
                    <measurement group_id="B3" value="30.5" lower_limit="29.3" upper_limit="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cervical dilation at admission</title>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.5" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B2" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="B3" value="1.25" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cervical dilation at enrollment</title>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="1.5" upper_limit="4"/>
                    <measurement group_id="B2" value="2.5" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B3" value="2.75" lower_limit="1.5" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tobacco use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior use of progesterone (17OHP-C)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Delivered Before 37 Weeks'</title>
        <time_frame>Duration of current pregnancy, anticipated maximum 18 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Micronized Progesterone Suppository</title>
            <description>Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository</title>
            <description>One placebo suppository vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Delivered Before 37 Weeks'</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Delivered Before 34 Weeks'</title>
        <description>Evaluated in women enrolled prior to 32 weeks gestation</description>
        <time_frame>Duration of current pregnancy, anticipated maximum 18 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Micronized Progesterone Suppository</title>
            <description>Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository</title>
            <description>One placebo suppository vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Delivered Before 34 Weeks'</title>
          <description>Evaluated in women enrolled prior to 32 weeks gestation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delivery Within 2 Weeks of Randomization</title>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Micronized Progesterone Suppository</title>
            <description>Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository</title>
            <description>One placebo suppository vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
          </group>
        </group_list>
        <measure>
          <title>Delivery Within 2 Weeks of Randomization</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.71</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>4.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Weeks Pregnancy Prolongation</title>
        <time_frame>Duration of current pregnancy, anticipated maximum 18 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Micronized Progesterone Suppository</title>
            <description>Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository</title>
            <description>One placebo suppository vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Weeks Pregnancy Prolongation</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="1.3" upper_limit="6.7"/>
                    <measurement group_id="O2" value="5.0" lower_limit="2.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infant Birth Weight</title>
        <time_frame>Day of delivery in current pregnancy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Micronized Progesterone Suppository - SINGLETON</title>
            <description>Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation in singleton subgroup.
Micronized progesterone suppository</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository - SINGLETON</title>
            <description>One placebo suppository vaginally daily until 36 6/7 weeks' gestation in singleton subgroup
Micronized progesterone suppository</description>
          </group>
          <group group_id="O3">
            <title>Micronized Progesterone Suppository - TWINS</title>
            <description>Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation in twin subgroup.
Micronized progesterone suppository</description>
          </group>
          <group group_id="O4">
            <title>Placebo Suppository - TWINS</title>
            <description>One placebo suppository vaginally daily until 36 6/7 weeks' gestation in twin subgroup
Micronized progesterone suppository</description>
          </group>
        </group_list>
        <measure>
          <title>Infant Birth Weight</title>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2454.9" spread="659.4"/>
                    <measurement group_id="O2" value="2523.1" spread="748.5"/>
                    <measurement group_id="O3" value="2164.4" spread="215.9"/>
                    <measurement group_id="O4" value="1974.1" spread="252.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Intensive Care Unit Admission</title>
        <time_frame>Followed for duration of neonatal hospital stay, estimated maximum 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Micronized Progesterone Suppository - SINGLETON</title>
            <description>Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation in singleton subgroup.
Micronized progesterone suppository</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository - SINGLETON</title>
            <description>One placebo suppository vaginally daily until 36 6/7 weeks' gestation in singleton subgroup
Micronized progesterone suppository</description>
          </group>
          <group group_id="O3">
            <title>Micronized Progesterone Suppository - TWINS</title>
            <description>Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation in twin subgroup.
Micronized progesterone suppository</description>
          </group>
          <group group_id="O4">
            <title>Placebo Suppository - TWINS</title>
            <description>One placebo suppository vaginally daily until 36 6/7 weeks' gestation in twin subgroup
Micronized progesterone suppository</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Intensive Care Unit Admission</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chorioamnionitis</title>
        <time_frame>Duration of current pregnancy, anticipated maximum 18 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Micronized Progesterone Suppository</title>
            <description>Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository</title>
            <description>One placebo suppository vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chorioamnionitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Neonatal Outcome</title>
        <description>A composite neonatal outcome comprising neonatal death, respiratory distress syndrome, bronchopulmonary dysplasia, severe (grade III/IV) interventricular hemorrhage, necrotizing enterocolitis, and sepsis.</description>
        <time_frame>Followed for duration of neonatal hospital stay, estimated maximum 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Micronized Progesterone Suppository - SINGLETON</title>
            <description>Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation in singleton subgroup.
Micronized progesterone suppository</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository - SINGLETON</title>
            <description>One placebo suppository vaginally daily until 36 6/7 weeks' gestation in singleton subgroup
Micronized progesterone suppository</description>
          </group>
          <group group_id="O3">
            <title>Micronized Progesterone Suppository - TWINS</title>
            <description>Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation in twin subgroup.
Micronized progesterone suppository</description>
          </group>
          <group group_id="O4">
            <title>Placebo Suppository - TWINS</title>
            <description>One placebo suppository vaginally daily until 36 6/7 weeks' gestation in twin subgroup
Micronized progesterone suppository</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Neonatal Outcome</title>
          <description>A composite neonatal outcome comprising neonatal death, respiratory distress syndrome, bronchopulmonary dysplasia, severe (grade III/IV) interventricular hemorrhage, necrotizing enterocolitis, and sepsis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Information about adverse events was collected from time of enrollment until discharge from the hospital after delivery for all participants, which is generally &lt; 1 week after delivery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Micronized Progesterone Suppository</title>
          <description>Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
        </group>
        <group group_id="E2">
          <title>Placebo Suppository</title>
          <description>One placebo suppository vaginally daily until 36 6/7 weeks' gestation.
Micronized progesterone suppository</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>Includes swelling of extremities, dizziness and fatigue</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vaginal irritation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Heather Frey</name_or_title>
      <organization>Ohio State University</organization>
      <phone>614-688-6798</phone>
      <email>Heather.Frey@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

